Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRXRXRecursion Pharmaceuticals$3.33+0.8%$3.34$2.77▼$7.18$1.77B118.29 million shs11.58 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRXRXRecursion Pharmaceuticals-7.30%-16.67%+4.76%-6.78%-37.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRXRXRecursion Pharmaceuticals$3.33+0.8%$3.34$2.77▼$7.18$1.77B118.29 million shs11.58 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRXRXRecursion Pharmaceuticals-7.30%-16.67%+4.76%-6.78%-37.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRXRXRecursion Pharmaceuticals 2.20Hold$8.10145.45% UpsideCurrent Analyst Ratings BreakdownLatest RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026RXRXRecursion Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$5.00 ➝ $5.505/7/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/30/2026RXRXRecursion Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$11.00 ➝ $10.004/21/2026RXRXRecursion Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRXRXRecursion Pharmaceuticals$74.68M23.42N/AN/A$2.14 per share1.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)Latest RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026RXRXRecursion Pharmaceuticals-$0.25N/AN/AN/A$11.20 millionN/A5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthRXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRXRXRecursion Pharmaceuticals0.015.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipRXRXRecursion Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRXRXRecursion Pharmaceuticals400529.91 million494.67 millionOptionableRXRX HeadlinesRecent News About These CompaniesCathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?4 hours ago | fool.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $158,400.00 in StockJuly 12 at 11:08 AM | americanbankingnews.com2 Beaten-Down Stocks That Still Aren't Worth BuyingJuly 11 at 6:46 PM | fool.comHsbc Holdings PLC Grows Position in Recursion Pharmaceuticals, Inc. $RXRXJuly 11 at 8:23 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 7.8% on Insider SellingJuly 10, 2026 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Rating of "Hold" by BrokeragesJuly 10, 2026 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 40,000 SharesJuly 9, 2026 | marketbeat.comIs Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?July 9, 2026 | finance.yahoo.comHere's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader MarketJuly 8, 2026 | finance.yahoo.comHere's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader MarketJuly 8, 2026 | zacks.com3 Cancer Stocks to Watch as Oncology Innovation AcceleratesJuly 8, 2026 | zacks.com5 Best Penny Stocks to Invest In According to BillionairesJuly 7, 2026 | insidermonkey.comRecursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug HopesJuly 5, 2026 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed?July 5, 2026 | finance.yahoo.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from BrokeragesJuly 5, 2026 | marketbeat.comDyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?July 4, 2026 | fool.comModerna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?July 3, 2026 | fool.comInvestors Purchase Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)July 1, 2026 | marketbeat.comShort interest alert: Most and least shorted sub-$2B healthcare stocks in June 2026July 1, 2026 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 8.5% - Should You Buy?July 1, 2026 | marketbeat.comRecursion Pharmaceuticals, Inc. $RXRX Shares Acquired by Hsbc Holdings PLCJune 29, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRXRX Company DescriptionsRecursion Pharmaceuticals NASDAQ:RXRX$3.32 +0.03 (+0.76%) As of 12:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Energy Stocks Racing to Fix AI's Power Problem No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings The Bond Market Just Sent Amazon a Message Investors Shouldn’t Ignore Insiders Sell 2 AI Enablers: Investors Can Buy Into Their Futures These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending These 3 Stocks Are Beating the Market in 2026 and Just Announced Hefty Dividend Increases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
